Internal Medicine, Hematology & Oncology · Honolulu, HI
NPI
1508833971
Since 2006
Specialty
Internal Medicine, Hematology & Oncology
Code 207RH0003X
Group practices
2
Medicare group memberships
Hospitals
5
Hospital affiliations
1329 Lusitana St Ste 307
Honolulu, HI, 96813
Phone (808) 524-6115
Groups this clinician bills Medicare through
Medicare paid, 2024
$1.5M
75,533 services
Medicare patients, 2024
593
Average age 76
Drug cost, 2024
$7.6M
1,760 prescriptions
Company payments, 2025
$4,809
From 61 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Melvin P Palalay was code J0897 (injection, denosumab, 1 mg), 5,959 times for 24 patients. In total Melvin P Palalay billed 75,533 services in 137 codes, and Medicare paid $1.5M.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2019-07-18.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| J0897 Injection, denosumab, 1 mg | Office | 5,959 | 24 | $20.74 | $124K |
| J0185 Injection, aprepitant, 1 mg | Office | 4,680 | 16 | $1.37 | $6,391 |
| J0885 Injection, epoetin alfa, (for non-esrd use), 1000 units | Office | 1,393 | 11 | $4.53 | $6,307 |
| 99214 Office E&M - Established | Office | 1,288 | 427 | $96.41 | $124K |
| 36415 Venipuncture Blood Collection | Office | 1,158 | 365 | $7.16 | $8,291 |
| 85025 Blood Count | Office | 1,146 | 353 | $7.43 | $8,520 |
| J1100 Injection, dexamethasone sodium phosphate, 1 mg | Office | 974 | 31 | $0.09 | $86.89 |
| 80053 Clinical Chemistry | Office | 542 | 205 | $10.05 | $5,446 |
| 80048 Clinical Chemistry | Office | 491 | 233 | $8.15 | $4,002 |
| J2469 Injection, palonosetron hcl, 25 mcg | Office | 480 | 19 | $0.58 | $277 |
| 80076 Clinical Chemistry | Office | 473 | 227 | $7.87 | $3,721 |
| J2405 Injection, ondansetron hydrochloride, per 1 mg | Office | 380 | 15 | $0.07 | $27.34 |
| 99213 Office E&M - Established | Office | 364 | 235 | $69.07 | $25K |
| 83735 Clinical Chemistry | Office | 362 | 156 | $6.47 | $2,341 |
| 84100 Clinical Chemistry | Office | 327 | 148 | $4.58 | $1,498 |
By year: 2022 $1.3M for 83,271 services; 2023 $361K for 18,526 services; 2024 $1.5M for 75,533 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 36415 Venipuncture Blood Collection | 1,158 | 365 | $7.16 | $8,291 |
| 85025 Blood Count | 1,146 | 353 | $7.43 | $8,520 |
| 80053 Clinical Chemistry | 542 | 205 | $10.05 | $5,446 |
| 80048 Clinical Chemistry | 491 | 233 | $8.15 | $4,002 |
| 80076 Clinical Chemistry | 473 | 227 | $7.87 | $3,721 |
| 83735 Clinical Chemistry | 362 | 156 | $6.47 | $2,341 |
| 84100 Clinical Chemistry | 327 | 148 | $4.58 | $1,498 |
| 84550 Clinical Chemistry | 311 | 145 | $4.34 | $1,348 |
| 83615 Clinical Chemistry | 217 | 102 | $5.82 | $1,264 |
| 84443 Clinical Chemistry | 198 | 60 | $16.38 | $3,243 |
Medicare prescription drug claims, 2024
In 2024, the drug Melvin P Palalay prescribed most often to Medicare patients was Xgeva (Denosumab), with 100 prescriptions and refills. In total Melvin P Palalay wrote 1,760 Medicare prescriptions that cost $7.6M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Xgeva Denosumab | 100 | 113 | 17 | $319K |
| Anastrozole Generic | 94 | 243 | 38 | $4,410 |
| Pantoprazole Sodium Generic | 58 | 102 | 31 | $430 |
| Keytruda Pembrolizumab | 57 | 64 | Under 11 | $823K |
| Alendronate Sodium Generic | 50 | 125 | 16 | $1,344 |
| Loperamide Loperamide Hcl | 41 | 41 | 30 | $347 |
| Pemetrexed Disodium Generic | 41 | 41 | Under 11 | $12K |
| Palonosetron Hcl Generic | 41 | 41 | Under 11 | $1,573 |
| Fosaprepitant Dimeglumine Generic | 40 | 40 | Under 11 | $5,384 |
| Ondansetron Odt Ondansetron | 33 | 33 | 23 | $450 |
| Letrozole Generic | 33 | 92 | Under 11 | $683 |
| Prolia Denosumab | 33 | 198 | 25 | $57K |
| Trazimera Trastuzumab-Qyyp | 31 | 31 | Under 11 | $104K |
| Exemestane Generic | 28 | 70 | 11 | $3,916 |
| Lupron Depot Leuprolide Acetate | 27 | 27 | Under 11 | $54K |
Brand drugs: 747 claims; generic drugs: 1,013 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Melvin P Palalay $4,809 ($4,809 in general payments such as food, travel and fees) from 61 companies. The largest payer was AstraZeneca Pharmaceuticals LP with $470.
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP AZN | 16 | $470 |
| E.R. Squibb & Sons, L.L.C. BMY | 10 | $263 |
| Novartis Pharmaceuticals Corporation NVS | 14 | $251 |
| Incyte Corporation INCY | 8 | $219 |
| Pfizer Inc. PFE | 10 | $210 |
| Abbvie Inc. ABBV | 11 | $193 |
| Caris MPI, Inc. | 2 | $175 |
| Lilly USA, LLC LLY | 5 | $161 |
| Janssen Biotech, Inc. JNJ | 6 | $154 |
| Daiichi Sankyo Inc. 4568.T | 7 | $149 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.